new indications for glp-1 drugs The expanding benefits of medicines: Cell Reports Medicine The New Weight Management Meds

The clinical difference is negligible

Higher concentration solutions provide a stronger diffusion gradient

Cardiometabolic risk prediction algorithms for young people with psychosis: a systematic review and exploratory analysis

Same-day surgery workflows may identify GLP-1 use too late for ideal planning

Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025

As the accessibility of these medications continues to rise and patient uptake increases, its crucial that we understand the neural mechanisms underlying the effects were seeing, said Lorenzo Leggio, MD, PhD, clinical director of NIHs National Institute on Drug Abuse